Literature DB >> 15201270

Reversible dilated cardiomyopathy associated with glucagonoma.

K Chang-Chretien1, J T Chew, D P Judge.   

Abstract

An association between dilated cardiomyopathy and glucagonoma has not previously been described. A case of a 54 year old woman with tachycardia and congestive heart failure is described. Initial evaluation included an echocardiogram, which showed dilated cardiomyopathy with an ejection fraction of 15%. Coronary angiography and endomyocardial biopsy did not identify a secondary cause of her cardiomyopathy. She subsequently developed necrolytic migratory erythema, and imaging of her pancreas identified a pancreatic mass with a major increase of her serum glucagon concentration. Tachycardia persisted despite treatment with beta blockers. After resection of her tumour, her heart rate normalised and subsequently her heart returned to normal size and function. Glucagon is used to treat overdoses of beta blockers and calcium channel blockers, increasing heart rate by increasing myocardial cyclic AMP concentrations. Although rare, in the appropriate clinical setting, glucagonoma should be considered in the differential diagnosis for tachycardia and dilated cardiomyopathy.

Entities:  

Mesh:

Year:  2004        PMID: 15201270      PMCID: PMC1768315          DOI: 10.1136/hrt.2004.036905

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Treatment of congestive heart failure with glucagon.

Authors:  H J Nord; A L Fontanes; J F Williams
Journal:  Ann Intern Med       Date:  1970-05       Impact factor: 25.391

2.  Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia.

Authors:  W A Corey; M L Markel; B D Hoit; R A Walsh
Journal:  Am Heart J       Date:  1993-12       Impact factor: 4.749

Review 3.  Utility of glucagon in the emergency department.

Authors:  C V Pollack
Journal:  J Emerg Med       Date:  1993 Mar-Apr       Impact factor: 1.484

Review 4.  The glucagonoma syndrome: a review of its features and discussion of new perspectives.

Authors:  M A Chastain
Journal:  Am J Med Sci       Date:  2001-05       Impact factor: 2.378

5.  Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart.

Authors:  Walter F Saavedra; Nazareno Paolocci; Marcus E St John; Michel W Skaf; Garrick C Stewart; Jin-Sheng Xie; Robert W Harrison; Joshua Zeichner; Daniel Mudrick; Eduardo Marbán; David A Kass; Joshua M Hare
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

6.  Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a classic presentation of pancreatic glucagonoma.

Authors:  Stephen P Povoski; Syed A Zaman; Barbara S Ducatman; David W McFadden
Journal:  W V Med J       Date:  2002 Jan-Feb

7.  Necrolytic migratory erythema as the only presenting sign of a glucagonoma.

Authors:  Sandra Marchese Johnson; Bruce R Smoller; Laura W Lamps; Thomas D Horn
Journal:  J Am Acad Dermatol       Date:  2003-08       Impact factor: 11.527

8.  Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells.

Authors:  A Sauvadet; T Rohn; F Pecker; C Pavoine
Journal:  Circ Res       Date:  1996-01       Impact factor: 17.367

  8 in total
  7 in total

1.  Glucagonoma and the glucagonoma syndrome.

Authors:  Xujun Song; Suli Zheng; Gang Yang; Guangbing Xiong; Zhe Cao; Mengyu Feng; Taiping Zhang; Yupei Zhao
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

Review 2.  Do glucagonomas always produce glucagon?

Authors:  Nicolai Jacob Wewer Albrechtsen; Benjamin G Challis; Ivan Damjanov; Jens Juul Holst
Journal:  Bosn J Basic Med Sci       Date:  2016-02-01       Impact factor: 3.363

3.  Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction.

Authors:  Safina Ali; John R Ussher; Laurie L Baggio; M Golam Kabir; Maureen J Charron; Olga Ilkayeva; Christopher B Newgard; Daniel J Drucker
Journal:  Mol Metab       Date:  2014-11-29       Impact factor: 7.422

4.  Glucagonoma-induced acute heart failure.

Authors:  Kun Zhang; Lukas J Lehner; Damaris Praeger; Gert Baumann; Fabian Knebel; Marcus Quinkler; Torsten K Roepke
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-11-01

5.  Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy.

Authors:  Michal Barabas; Isabel Huang-Doran; Debbie Pitfield; Hazel Philips; Manoj Goonewardene; Ruth T Casey; Benjamin G Challis
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-03-05

6.  Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study.

Authors:  Ramin Tehranchi; Jonas Pettersson; Anita E Melgaard; Friedeborg Seitz; Anders Valeur; Stine Just Maarbjerg
Journal:  Curr Ther Res Clin Exp       Date:  2022-03-29

7.  How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

Authors:  Carmen Sorina Martin; Ovidiu Dumitru Parfeni; Liliana Gabriela Popa; Mara Madalina Mihai; Dana Terzea; Vlad Herlea; Mirela Gherghe; Razvan Adam; Osama Alnuaimi; Valentin Calu; Adrian Miron; Silvius Negoita; Cornelia Nitipir; Simona Fica
Journal:  Diagnostics (Basel)       Date:  2022-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.